Jing Su

Title: Innovations of Jing Su in Pharmaceutical Sciences

Introduction

Jing Su is a notable inventor based in Guangdong, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of innovative binding conjugates and antibodies. With a total of 2 patents, his work focuses on enhancing immune responses and targeting tumor cells.

Latest Patents

Jing Su's latest patents include a multi-specific binding conjugate and a bispecific antibody. The multi-specific binding conjugate is designed to modulate immune responses and treat various diseases, including cancer and autoimmune conditions. This invention comprises binding moieties for multiple receptors or antigens, coupled by a nanomaterial. The bispecific antibody is capable of enhancing tumor-killing capabilities by combining with immune cells. This innovative approach connects antibodies and degradable nanoparticles, allowing for targeted treatment of tumor cells.

Career Highlights

Jing Su is currently associated with Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. His work at this company emphasizes the application of his patented technologies in real-world medical scenarios. His research aims to improve therapeutic outcomes for patients suffering from complex diseases.

Collaborations

Jing Su collaborates with talented individuals in his field, including Haoyang Yu and Zhengcheng Li. These partnerships enhance the innovative potential of his projects and contribute to the advancement of pharmaceutical research.

Conclusion

Jing Su's contributions to pharmaceutical innovations demonstrate his commitment to improving healthcare through advanced technologies. His patents reflect a deep understanding of immune modulation and targeted therapies, paving the way for future advancements in the field.